

COMBINATION OF OLOPATADINE AND MOMETAZONE IN THE TREATMENT OF ALLERGIC RHINITIS

A. Ye. Bogomolov

National Pirogov memorial medical university, Vinnytsya, Ukraine

Abstract. Numerous scientific studies have shown that allergic diseases dramatically reduce the quality of life not only of patients but also of their families. People with this pathology are in extremely unfavorable conditions: the disease affects personal development, career and life style. Treatment of allergic rhinitis (AR) should be comprehensive and aimed at improving the quality of life of the patient. One of the most important guidelines for the management of patients with AR world wide is ARIA (Allergic Rhinitis and its Impact on Asthma), which has been developed by a team of international experts and has been constantly updated over the past 15 years. At values of the visual analog scale VAS ≥ 5 , the recommended treatment is the use of intranasal H_1 -histamine blocker in combination with intranasal glucocorticosteroid. One of the new combinations that qualitatively corresponds to this composition is the combination of olopatadine hydrochloride and mometasone furoate in the form of a nasal spray, which has a rapid onset of action, acceptable safety profile, proven clinical efficacy in patients with moderate and severe seasonal AR.

Key words: allergic rhinitis, quality of life, therapy, combination of olopatadine and mometasone.

Artemii Ye. Bogomolov

National Pirogov memorial medical university

Candidate of Medical Sciences, associate professor of phthysiology, clinical immunology and allergy department

56, Pirogova str., 21000, Vinnytsya, Ukraine,

e-mail: art.bogomolov@gmail.com

Asthma and Allergy, 2021, 1, P. 32–39.